Sucralfate

Should be taken on an empty stomach. Take on an empty stomach 1 hr before or 2 hr after meals.

Patient with diabetes mellitus; conditions that may impair swallowing (e.g. recent or long-term intubation, dysphagia, tracheostomy, history of aspiration), or other conditions that may alter gag/cough reflex or reduce oropharyngeal coordination or motility. Patients who are seriously ill, particularly those with delayed gastric emptying and concurrent enteral feedings. Treatment guidelines may vary among individual products (refer to product-specific recommendations). Renal impairment (e.g. chronic renal failure or those receiving dialysis). Elderly. Pregnancy and lactation. Monitoring Parameters Monitor blood glucose levels in diabetic patients taking the oral susp. Monitor Al phosphate, Ca and alkaline phosphatase periodically, and signs of Al toxicity in patients with renal impairment.

Significant: Increased risk of Al accumulation and toxicity such as Al osteodystrophy, osteomalacia and encephalopathy (in patients renal with impairment); bezoar formation and intestinal obstruction (in seriously ill patients); hyperglycaemia (susp); aspiration accompanied with respiration complications (tab). Ear and labyrinth disorders: Vertigo. Gastrointestinal disorders: Constipation, diarrhoea, flatulence, gastric discomfort, dry mouth, dyspepsia, nausea, vomiting. Immune system disorders: Hypersensitivity reactions (e.g. dyspnoea, urticaria, anaphylaxis). Musculoskeletal and connective tissue disorders: Back pain. Nervous system disorders: Dizziness, drowsiness, headache. Psychiatric disorders: Insomnia. Skin and subcutaneous tissue disorders: Pruritus, rash.

May decrease the absorption of digoxin, quinidine, fluoroquinolones, tetracycline, ketoconazole, sulpiride, levothyroxine, phenytoin, ranitidine, cimetidine, warfarin and theophylline; consider dosing interval of at least 2 hours between sucralfate and other concomitant non-antacid drugs. May increase the total body burden of Al when concomitantly used with other preparation that contains Al (e.g. Al-containing antacids). If antacids are concurrently needed, a dosing interval of 30 minutes between sucralfate and antacids is recommended.

Antacids, Antireflux Agents & Antiulcerants

A02BX02 - sucralfate ; Belongs to the class of other drugs used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).